Development
Sarepta Therapeutics, Inc.
SRPT
$16.75
-$0.35-2.05%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 33.26% | 26.13% | 20.15% | 27.41% | 32.93% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 33.26% | 26.13% | 20.15% | 27.41% | 32.93% |
| Cost of Revenue | 1.05% | 3.16% | 16.66% | 22.39% | 17.21% |
| Gross Profit | 356.47% | 157.89% | 23.97% | 12.48% | 49.31% |
| SG&A Expenses | 6.75% | 15.07% | 24.42% | 73.02% | 59.70% |
| Depreciation & Amortization | 118.35% | 36.55% | 0.00% | 0.00% | 1.13% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.85% | 6.63% | 18.87% | 34.75% | 27.64% |
| Operating Income | 50.05% | 25.32% | -16.45% | -49.00% | -19.37% |
| Income Before Tax | 24.62% | 6.86% | -76.29% | -208.83% | -64.69% |
| Income Tax Expenses | 17.40% | 412.43% | 392.99% | 1,854.45% | 8,150.60% |
| Earnings from Continuing Operations | 23.81% | 3.54% | -79.16% | -212.78% | -67.99% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 23.81% | 3.54% | -79.16% | -212.78% | -67.99% |
| EBIT | 50.05% | 25.32% | -16.45% | -49.00% | -19.37% |
| EBITDA | 54.80% | 27.90% | -17.60% | -53.71% | -20.19% |
| EPS Basic | 24.04% | 4.58% | -75.69% | -198.84% | -56.07% |
| Normalized Basic EPS | 55.95% | 37.11% | 2.37% | -24.20% | -3.38% |
| EPS Diluted | 23.36% | 4.63% | -75.54% | -198.92% | -56.14% |
| Normalized Diluted EPS | 55.43% | 37.11% | 2.37% | -24.20% | -3.38% |
| Average Basic Shares Outstanding | 2.63% | 1.53% | 3.46% | 5.51% | 7.75% |
| Average Diluted Shares Outstanding | 6.05% | 1.53% | 3.46% | 5.51% | 7.75% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |